Indian Journal of Public Health

REVIEW ARTICLE
Year
: 2020  |  Volume : 64  |  Issue : 6  |  Page : 125--127

Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?


Praveen Balabaskaran Nina1, Aditya Prasad Dash2 
1 Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India
2 Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India

Correspondence Address:
Aditya Prasad Dash
Central University of Tamil Nadu, Tiruvarur, Tamil Nadu
India

Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.


How to cite this article:
Nina PB, Dash AP. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?.Indian J Public Health 2020;64:125-127


How to cite this URL:
Nina PB, Dash AP. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?. Indian J Public Health [serial online] 2020 [cited 2021 Sep 17 ];64:125-127
Available from: https://www.ijph.in/article.asp?issn=0019-557X;year=2020;volume=64;issue=6;spage=125;epage=127;aulast=Nina;type=0